HK1217949A1 - 雙重選擇性 δ和γ激酶抑制劑 - Google Patents

雙重選擇性 δ和γ激酶抑制劑

Info

Publication number
HK1217949A1
HK1217949A1 HK16105982.1A HK16105982A HK1217949A1 HK 1217949 A1 HK1217949 A1 HK 1217949A1 HK 16105982 A HK16105982 A HK 16105982A HK 1217949 A1 HK1217949 A1 HK 1217949A1
Authority
HK
Hong Kong
Prior art keywords
delta
kinase inhibitors
dual selective
gamma kinase
gamma
Prior art date
Application number
HK16105982.1A
Other languages
English (en)
Inventor
Swaroop K V S Vakkalanka
Prashant K Bhavar
Srikant Viswanadha
Govindarajulu Babu
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of HK1217949A1 publication Critical patent/HK1217949A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
HK16105982.1A 2013-06-07 2016-05-25 雙重選擇性 δ和γ激酶抑制劑 HK1217949A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2501CH2013 2013-06-07
IN5567CH2013 2013-12-03
PCT/IB2014/061954 WO2014195888A1 (en) 2013-06-07 2014-06-04 Dual selective pi3 delta and gamma kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1217949A1 true HK1217949A1 (zh) 2017-01-27

Family

ID=50980341

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105982.1A HK1217949A1 (zh) 2013-06-07 2016-05-25 雙重選擇性 δ和γ激酶抑制劑

Country Status (31)

Country Link
US (3) US9790224B2 (zh)
EP (1) EP3004106B1 (zh)
JP (1) JP6499165B2 (zh)
KR (1) KR102292853B1 (zh)
CN (1) CN105358560B (zh)
AP (1) AP2015008888A0 (zh)
AR (1) AR096543A1 (zh)
AU (1) AU2014276476B2 (zh)
BR (1) BR112015030385B1 (zh)
CA (1) CA2913226C (zh)
CL (1) CL2015003562A1 (zh)
CY (1) CY1119615T1 (zh)
DK (1) DK3004106T3 (zh)
EA (1) EA029017B1 (zh)
ES (1) ES2648094T3 (zh)
HK (1) HK1217949A1 (zh)
HR (1) HRP20171795T1 (zh)
HU (1) HUE035237T2 (zh)
IL (1) IL242761B (zh)
LT (1) LT3004106T (zh)
MX (1) MX366449B (zh)
NO (1) NO3004106T3 (zh)
PH (1) PH12015502698B1 (zh)
PL (1) PL3004106T3 (zh)
PT (1) PT3004106T (zh)
RS (1) RS56606B1 (zh)
SG (1) SG11201509992RA (zh)
SI (1) SI3004106T1 (zh)
TW (1) TWI615144B (zh)
WO (1) WO2014195888A1 (zh)
ZA (1) ZA201508708B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res SPECIFIC ANTIBODIES AND USES THEREOF
RS56606B1 (sr) * 2013-06-07 2018-02-28 Rhizen Pharmaceuticals S A Dvojno selektivni inhibitori pi3 kinaze delta i gama
US9663499B2 (en) 2013-06-07 2017-05-30 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
AU2015360583B2 (en) 2014-12-10 2020-01-23 The Scripps Research Institute Small molecule inhibitors of fibrosis
US20170360796A1 (en) * 2014-12-23 2017-12-21 Pharmacyclics Llc Btk inhibitor combinations and dosing regimen
EP3720557A1 (en) * 2017-12-06 2020-10-14 Rhizen Pharmaceuticals S.A. Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
EP4149629A1 (en) 2020-05-14 2023-03-22 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
WO2023125419A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种己二酸盐结晶及其制备方法
WO2023125418A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种苯磺酸盐结晶及其制备方法
TW202328132A (zh) * 2021-12-31 2023-07-16 大陸商同潤生物醫藥(上海)有限公司 ＰＩ３Ｋδ／γ雙重抑制劑化合物的半富馬酸鹽結晶及其製備方法
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法
WO2023209634A1 (en) 2022-04-29 2023-11-02 Rhizen Pharmaceuticals Ag A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP2705029B1 (en) 2011-05-04 2018-10-24 Rhizen Pharmaceuticals S.A. Novel compounds as modulators of protein kinases
EA032812B1 (ru) 2012-05-04 2019-07-31 Ризен Фармасьютикалз Са Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов
RS56606B1 (sr) * 2013-06-07 2018-02-28 Rhizen Pharmaceuticals S A Dvojno selektivni inhibitori pi3 kinaze delta i gama
EP3720557A1 (en) * 2017-12-06 2020-10-14 Rhizen Pharmaceuticals S.A. Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Also Published As

Publication number Publication date
HRP20171795T1 (hr) 2018-01-26
EA029017B1 (ru) 2018-01-31
BR112015030385A2 (pt) 2017-07-25
MX366449B (es) 2019-07-09
AU2014276476A1 (en) 2015-12-10
BR112015030385B1 (pt) 2020-08-18
AU2014276476B2 (en) 2018-05-10
KR102292853B1 (ko) 2021-08-24
PH12015502698A1 (en) 2016-03-14
ZA201508708B (en) 2017-02-22
TWI615144B (zh) 2018-02-21
EP3004106A1 (en) 2016-04-13
CA2913226A1 (en) 2014-12-11
AR096543A1 (es) 2016-01-13
CN105358560B (zh) 2017-03-08
US9790224B2 (en) 2017-10-17
IL242761B (en) 2018-11-29
JP2016520644A (ja) 2016-07-14
US20140364447A1 (en) 2014-12-11
MX2015016741A (es) 2016-11-14
ES2648094T3 (es) 2017-12-28
US10851107B2 (en) 2020-12-01
RS56606B1 (sr) 2018-02-28
SG11201509992RA (en) 2016-01-28
US11466006B2 (en) 2022-10-11
AP2015008888A0 (en) 2015-11-30
CA2913226C (en) 2023-01-03
PL3004106T3 (pl) 2018-01-31
PH12015502698B1 (en) 2016-03-14
BR112015030385A8 (pt) 2019-12-24
TW201517908A (zh) 2015-05-16
US20210032248A1 (en) 2021-02-04
CY1119615T1 (el) 2018-04-04
NZ714465A (en) 2021-03-26
EA201592113A1 (ru) 2016-05-31
DK3004106T3 (en) 2017-12-04
EP3004106B1 (en) 2017-08-30
CL2015003562A1 (es) 2016-08-05
KR20160017047A (ko) 2016-02-15
JP6499165B2 (ja) 2019-04-10
NO3004106T3 (zh) 2018-01-27
LT3004106T (lt) 2018-02-26
SI3004106T1 (en) 2018-03-30
PT3004106T (pt) 2017-11-27
US20170334914A1 (en) 2017-11-23
CN105358560A (zh) 2016-02-24
HUE035237T2 (hu) 2018-05-02
WO2014195888A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and their uses
HK1217949A1 (zh) 雙重選擇性 δ和γ激酶抑制劑
HK1223089A1 (zh) 激酶抑制劑及其用途
HK1217198A1 (zh) 蛋白激酶抑制劑
HK1220459A1 (zh) 激酶抑制劑
IL238564A0 (en) Combination of an antibody against 20cd with a selective pi3 kinase inhibitor
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
HK1219104A1 (zh) 激酶抑制劑
HK1219057A1 (zh) 大環的鹽可誘導的激酶抑制劑
EP2986611A4 (en) CERTAIN PROTEIN KINASE INHIBITORS
EP2964225A4 (en) CAMKII INHIBITORS AND USES THEREOF
HUE050878T2 (hu) Anti-CD20 antitest és PIK3 kináz szelektív inhibitor kombinációja
GB201307155D0 (en) Kinase inhibitors
GB201304086D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304083D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304084D0 (en) Selective glycosidase inhibitors and uses thereof